Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  MUMBAI STOCK EXCHANGE  >  Dr. Reddy's Laboratories Limited    500124   INE089A01023

DR. REDDY'S LABORATORIES LIMITED

(500124)
  Report
End-of-day quote. End-of-day quote MUMBAI STOCK EXCHANGE - 01/22
5033.8 INR   -0.37%
01/21Asian ADRs Nudge Lower in Thursday Trading
MT
01/20Asian ADRs Climb Higher in Wednesday Trading
MT
01/19Asian ADRs Climb Higher in Tuesday Trading
MT
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dr Reddy's isolates data center services after cyberattack

10/22/2020 | 03:01am EST
FILE PHOTO: Man holds laptop computer as cyber code is projected on him in this illustration picture

BENGALURU (Reuters) - Indian drugmaker Dr Reddy's Laboratories Ltd said on Thursday it had isolated all its data center services as a preventive measure following a cyberattack.

Shares of the company, which has a partnership to run clinical trials of Russia's Sputnik-V COVID-19 vaccine in India, fell as much as 4.3% after local television channel ET Now first reported the news.

"We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident," Dr Reddy's Chief Information Officer Mukesh Rathi said in a statement.

Dr Reddy's, India's No.2 drugmaker by market value, had shut its key plants globally due to the breach at its servers, ET Now had reported, citing sources.

Its plants in the United States, United Kingdom, Brazil, India and Russia were impacted, the report added.

Hyderabad-based Dr Reddy's also has tie-ups with global firms to sell coronavirus treatments remdesivir and favipiravir in India besides its partnership for the Sputnik-V vaccine.

Dr Reddy's did not respond to a Reuters email seeking more details.

(Reporting by Nallur Sethuraman and Anuron Kumar Mitra in Bengaluru; Editing by Sriraj Kalluvila)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED -0.37% 5033.8 End-of-day quote.-3.27%
EURO / BRAZILIAN REAL (EUR/BRL) 2.24% 6.6542 Delayed Quote.2.58%
FUJIFILM HOLDINGS CORPORATION 1.60% 6287 End-of-day quote.15.61%
GILEAD SCIENCES, INC. -0.06% 66.94 Delayed Quote.14.90%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.07% 75.172 Delayed Quote.0.19%
All news about DR. REDDY'S LABORATORIES LIMITED
01/21Asian ADRs Nudge Lower in Thursday Trading
MT
01/20Asian ADRs Climb Higher in Wednesday Trading
MT
01/19Asian ADRs Climb Higher in Tuesday Trading
MT
01/15DR REDDY LABORATORIES : Receives Approval to Conduct Phase 3 Clinical Trial of S..
MT
01/15DR REDDY LABORATORIES : . Reddy's Receives Approval to Conduct Phase 3 Clinical ..
BU
01/12Asian ADRs Move Higher in Tuesday Trading
MT
01/12DR REDDY LABORATORIES : to present at the 39th Annual J.P. Morgan Healthcare Con..
PU
01/12Indian Indices Gain on Tuesday's Closing; Force Motors Rises 3%
MT
01/12DR REDDY LABORATORIES : Gets Nod for Phase-III Clinical Tiral of COVID-19 Vaccin..
MT
01/11DR REDDY LABORATORIES : . Reddy's Says Russia's COVID-19 Vaccine Meets Safety En..
MT
More news
Financials
Sales 2021 193 B 2 638 M 2 638 M
Net income 2021 27 765 M 380 M 380 M
Net cash 2021 10 221 M 140 M 140 M
P/E ratio 2021 30,1x
Yield 2021 0,51%
Capitalization 835 B 11 443 M 11 445 M
EV / Sales 2021 4,28x
EV / Sales 2022 3,69x
Nbr of Employees 21 650
Free-Float 67,1%
Chart DR. REDDY'S LABORATORIES LIMITED
Duration : Period :
Dr. Reddy's Laboratories Limited Technical Analysis Chart | 500124 | INE089A01023 | MarketScreener
Technical analysis trends DR. REDDY'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 33
Average target price 5 678,84 INR
Last Close Price 5 033,80 INR
Spread / Highest target 27,1%
Spread / Average Target 12,8%
Spread / Lowest Target -20,5%
EPS Revisions
Managers and Directors
NameTitle
Erez Israeli Chief Executive & Operating Officer
Satish Kallam Reddy Co-Chairman
Gunupati Venkateswara Prasad Co-Chairman & Managing Director
Parag Agarwal Chief Financial Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR. REDDY'S LABORATORIES LIMITED-3.27%11 443
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159